A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth

Seiji Kawa, Hirohisa Matsushita, Hirokazu Ohbayashi, Kentaro Senba, Tadashi Yamamoto

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC50 values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab.

    Original languageEnglish
    Pages (from-to)329-333
    Number of pages5
    JournalBiochemical and Biophysical Research Communications
    Volume384
    Issue number3
    DOIs
    Publication statusPublished - 2009 Jul 3

    Fingerprint

    Monoclonal Antibodies
    Breast Neoplasms
    Growth
    Cells
    Molecular Targeted Therapy
    Tumors
    Epitopes
    Assays
    Agglomeration
    Binding Sites
    Cell Proliferation
    Recurrence
    Cell Line
    Pharmaceutical Preparations
    Trastuzumab
    Neoplasms
    Therapeutics

    Keywords

    • 6G10
    • Breast cancer
    • ErbB2
    • Molecular therapeutics
    • Preclinical study
    • Trastuzumab

    ASJC Scopus subject areas

    • Biochemistry
    • Biophysics
    • Cell Biology
    • Molecular Biology

    Cite this

    A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth. / Kawa, Seiji; Matsushita, Hirohisa; Ohbayashi, Hirokazu; Senba, Kentaro; Yamamoto, Tadashi.

    In: Biochemical and Biophysical Research Communications, Vol. 384, No. 3, 03.07.2009, p. 329-333.

    Research output: Contribution to journalArticle

    Kawa, Seiji ; Matsushita, Hirohisa ; Ohbayashi, Hirokazu ; Senba, Kentaro ; Yamamoto, Tadashi. / A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth. In: Biochemical and Biophysical Research Communications. 2009 ; Vol. 384, No. 3. pp. 329-333.
    @article{3f6ddcefc8c24914a559c0cfc583f098,
    title = "A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth",
    abstract = "Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC50 values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab.",
    keywords = "6G10, Breast cancer, ErbB2, Molecular therapeutics, Preclinical study, Trastuzumab",
    author = "Seiji Kawa and Hirohisa Matsushita and Hirokazu Ohbayashi and Kentaro Senba and Tadashi Yamamoto",
    year = "2009",
    month = "7",
    day = "3",
    doi = "10.1016/j.bbrc.2009.04.118",
    language = "English",
    volume = "384",
    pages = "329--333",
    journal = "Biochemical and Biophysical Research Communications",
    issn = "0006-291X",
    publisher = "Academic Press Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth

    AU - Kawa, Seiji

    AU - Matsushita, Hirohisa

    AU - Ohbayashi, Hirokazu

    AU - Senba, Kentaro

    AU - Yamamoto, Tadashi

    PY - 2009/7/3

    Y1 - 2009/7/3

    N2 - Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC50 values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab.

    AB - Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC50 values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab.

    KW - 6G10

    KW - Breast cancer

    KW - ErbB2

    KW - Molecular therapeutics

    KW - Preclinical study

    KW - Trastuzumab

    UR - http://www.scopus.com/inward/record.url?scp=65649112936&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=65649112936&partnerID=8YFLogxK

    U2 - 10.1016/j.bbrc.2009.04.118

    DO - 10.1016/j.bbrc.2009.04.118

    M3 - Article

    VL - 384

    SP - 329

    EP - 333

    JO - Biochemical and Biophysical Research Communications

    JF - Biochemical and Biophysical Research Communications

    SN - 0006-291X

    IS - 3

    ER -